On the 6-month chart, it shows that the stockprice closed right up at the upper Bollinger Band at 1.64, so hopefully the stock continues to ride that upper line upward for some days to come before pulling back to catch a "breather."
The 200 dma (not shown in my chart below, but later Stockcharts will re-set my chart to simpler parameters and it will show) is gently declining, presently at 1.72, so there will likely be "an encounter" next week between shareprice and that line of resistance, maybe around the 1.68-1.69 level. The 50dma has finally turned up after a LONG decline. The shareprice has obviously surpassed the 10dma, 20dma and recently that 50dma. So that's all bullish.
The Parabolic SAR indicator switched from "sell" to "Buy" on Jan. 28, and the trigger point back to a "sell" is way down at 1.22, just below the 50dma, so the stock would have to fall down a lot to trigger that. The P-SAR is not rising very fast, either, so the shareprice is likely "safe" for at least a couple of weeks on that score :-)
RSI hit 70 today, which is officially the beginning of "overbought" territory, but obviously long-depressed stocks or, on the other hand, high-achieving stocks, can go up well into the 70s, 80s or even 90s for fair amounts of time, sometimes weeks, with occasional dips into the 60s to consolidate and gather steam for next leg up.
MACD line and Accum/Distribute line have lots of room still to move up much higher, especially the latter.
I think France launch news could take APRI well above the 200dma and create a long "Buy" signal on the P-SAR. That would be reinforced by a Spain launch.
Overall, i think APRI stands a great chance of being back in the $2s for much of the Spring.
Let's hope we don't see another repeated hammering down of the biotech sector like we saw last year in Winter and Spring.
Market Data 
Markets 
AI
